Wainwright: Argenx's Vyvgart Could 'Achieve Blockbuster Status'
- HC Wainwright is bullish on Argenx SE's Vyvgart (efgartigimod). "We think it's becoming obvious that Vyvgart is going to be a blockbuster sooner rather than later, as it establishes leadership in gMG and is poised to add new indications as well as a more patient-friendly SC formulation over the next 2-3 years," HC Wainwright notes.
- It raised the price target to $425 from $400.
- Vyvgart is approved for generalized myasthenia gravis (gMG), characterized by weakness and rapid fatigue of any of the muscles under your voluntary control.
- But at the beginning of the year, there was some uncertainty regarding the shape of its launch curve. Argenx posted Q2 sales of $75 million, nearly 3x the analyst's estimate of $27 million.
- Roughly 1,400 patients are on therapy globally, well past the 600 the analyst modeled.
- European approval is expected in 3Q. The application for SC efgartigimod in gMG remains on track to be filed by year-end. Topline data from the registrational trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy is due in 1Q23.
- HC Wainwright raised estimates for Vyvgart to $341 million for 2022, $684 million for 2023, and $1.16 billion in 2024, up from $113 million, $330 million, and $686 million, respectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.